Prognostic factors in 1,521 melanoma patients with distant metastases - PubMed (original) (raw)
. 1995 Sep;181(3):193-201.
Affiliations
- PMID: 7670677
Prognostic factors in 1,521 melanoma patients with distant metastases
A Barth et al. J Am Coll Surg. 1995 Sep.
Abstract
Background: Although over 7,000 people die from malignant melanoma each year, there are limited prognostic data for patients with metastatic disease. A retrospective analysis was undertaken to identify variables that accurately predict outcome and to determine if the survival rate of patients with melanoma treated for distant metastases (American Joint Committee on Cancer [AJCC] stage IV disease) at the authors' institution changed between 1971 and 1993.
Study design: Data for 1,521 patients with AJCC stage IV melanoma treated by the staff of the John Wayne Cancer Institute were reviewed, and a univariate and multivariate survival analysis against ten clinical and pathological variables was performed using the Cox proportional hazard regression model.
Results: The median survival time of the 1,521 patients was 7.5 months; the estimated five-year survival rate was 6 percent. Three independent variables predicted survival: initial site of metastases (p < 0.0001); disease-free interval before distant metastases (p = 0.0001); and stage of disease preceding distant metastases (p = 0.0001). Patients could be divided into three distinct prognostic groups based on the initial site of metastases: cutaneous, nodal, or gastrointestinal metastases (median survival of 12.5 months; estimated five-year survival rate 14 percent); pulmonary metastases (median survival of 8.3 months; estimated five-year survival rate 4 percent); and metastases to the liver, brain, or bone (median survival of 4.4 months; estimated five-year survival rate 3 percent). There was no significant change in the survival rate of patients with AJCC stage IV melanoma during the 22-year review period.
Conclusions: Despite new treatment options, the survival rate of patients with metastatic melanoma has not changed significantly over the last 22 years; their prognosis remains dismal. The three prognostic variables identified in this study should be considered in the design of future clinical trials.
Comment in
- Prognosis of patients with advanced melanoma.
Eberlein TJ. Eberlein TJ. J Am Coll Surg. 1995 Sep;181(3):263-5. J Am Coll Surg. 1995. PMID: 7670686 No abstract available.
Similar articles
- Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma.
Francken AB, Accortt NA, Shaw HM, Wiener M, Soong SJ, Hoekstra HJ, Thompson JF. Francken AB, et al. Ann Surg Oncol. 2008 May;15(5):1476-84. doi: 10.1245/s10434-007-9717-9. Epub 2008 Jan 15. Ann Surg Oncol. 2008. PMID: 18196345 - Contemporary surgical treatment of advanced-stage melanoma.
Essner R, Lee JH, Wanek LA, Itakura H, Morton DL. Essner R, et al. Arch Surg. 2004 Sep;139(9):961-6; discussion 966-7. doi: 10.1001/archsurg.139.9.961. Arch Surg. 2004. PMID: 15381613 - Metastasectomy in malignant melanoma.
Karakousis CP, Velez A, Driscoll DL, Takita H. Karakousis CP, et al. Surgery. 1994 Mar;115(3):295-302. Surgery. 1994. PMID: 8128354 - [Surgery of pulmonary metastasis from malignant melanoma. Results and criteria of surgical excision].
Delaunay MM, Amici JM, Avril MF, Avril A, Barrut D, Blanc L, Blondet R, Bonichon E, Carolus JM, Depadt G, et al. Delaunay MM, et al. Ann Dermatol Venereol. 1991;118(4):287-95. Ann Dermatol Venereol. 1991. PMID: 2069340 Review. French. - Metastatic uveal melanoma: is there a role for conventional chemotherapy? - A single center study based on 58 patients.
Pons F, Plana M, Caminal JM, Pera J, Fernandes I, Perez J, Garcia-Del-Muro X, Marcoval J, Penin R, Fabra A, Piulats JM. Pons F, et al. Melanoma Res. 2011 Jun;21(3):217-22. doi: 10.1097/CMR.0b013e3283457726. Melanoma Res. 2011. PMID: 21467954 Review.
Cited by
- Immature mediastinal teratoma with unusual histopathology: A case report of multi-lineage, somatic-type malignant transformation and a review of the literature.
Mustafa OM, Mohammed SF, Aljubran A, Saleh WN. Mustafa OM, et al. Medicine (Baltimore). 2016 Jun;95(26):e3378. doi: 10.1097/MD.0000000000003378. Medicine (Baltimore). 2016. PMID: 27367976 Free PMC article. Review. - Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors.
Tas F. Tas F. J Oncol. 2012;2012:647684. doi: 10.1155/2012/647684. Epub 2012 Jun 27. J Oncol. 2012. PMID: 22792102 Free PMC article. - Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). The new American Joint Committee on Cancer.
Lotem M, Peretz T, Drize O, Gimmon Z, Ad El D, Weitzen R, Goldberg H, Ben David I, Prus D, Hamburger T, Shiloni E. Lotem M, et al. Br J Cancer. 2002 May 20;86(10):1534-9. doi: 10.1038/sj.bjc.6600251. Br J Cancer. 2002. PMID: 12085200 Free PMC article. Clinical Trial. - Translating Molecules into Imaging-The Development of New PET Tracers for Patients with Melanoma.
Vercellino L, de Jong D, Dercle L, Hosten B, Braumuller B, Das JP, Deng A, Moya-Plana A, A'Keen C, Yeh R, Merlet P, Baroudjian B, Salvatore MM, Capaccione KM. Vercellino L, et al. Diagnostics (Basel). 2022 Apr 29;12(5):1116. doi: 10.3390/diagnostics12051116. Diagnostics (Basel). 2022. PMID: 35626272 Free PMC article. Review. - Treatment outcomes of advanced stage malignant melanoma in hand and foot after amputation in Korean patients.
Cho K, Jung ST. Cho K, et al. Clin Orthop Surg. 2013 Dec;5(4):314-20. doi: 10.4055/cios.2013.5.4.314. Epub 2013 Nov 18. Clin Orthop Surg. 2013. PMID: 24340152 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Other Literature Sources
Medical